REMARKS/ARGUMENTS

Claims 1-92 are pending. The Examiner has imposed a Restriction Requirement between:

Group I: Claims 1-20, drawn to a research model for screening compounds suspected of modulating the CD40L/CD40R signaling pathway;

Group II: Claims 21-39, drawn to a research model for screening compounds suspected of modulating the CD40L/CD40R signaling pathway;

Group III: Claims 40-53, drawn to a method of identifying compounds that ameliorate symptoms associated with a disease;

Group IV: Claims 54-70, drawn to a method of treating a disease; and

Group V: Claims 71-92, drawn to a method of causing a desired biological effect.

Applicant elects Group I, claims 1-20, without traverse.

Applicant further elects the following species for examination:

- A. animal;
- B. cells: central nervous system cells;
- C. marker: cytokine and in particular tumor necrosis factor;
- D. compound: a compound that binds to CD40L; and
- E. disease: neuronal inflammation.

Claims readable on the elected species include claims 1-4, 8, 16 and 19-20.

Appl. No. 10/694,634 Amendment dated September 25, 2006 Reply to Office Action of April 24, 2006

Examination of the elected claims is respectfully requested. The Commissioner is authorized to charge any additional fees, or to credit any overpayment, to Deposit Account No. 11-0980.

Respectfully submitted,

Madeline'l. Johnston, Esq. Reg. No. 36,174

Date: September 25, 2006

L

KING & SPALDING LLP 1180 Peachtree Street 34th Floor Atlanta, Georgia 30309

Tel.: (404) 572-3541